CDC-RFA-PS-24-0003: Support and Scale Up of HIV Prevention Services in Sexual Health Clinics
Closed
This grant is closed. A newer notice from the same program is forecast: Controlling and Preventing STIs in US Health Departments (CAP-STIs) (CDC-RFA-PS-27-0008). Status: Expected deadline January 11, 2027. It is in our archive of Centers for Disease Control - NCHHSTP notices from 2023.
Centers for Disease Control - NCHHSTP offered grants to any type of organization. It expected to make about 20 awards worth $100 million in total. Applications closed on January 16, 2024.
From the official notice on Grants.gov, last changed January 9, 2024. Checked November 7, 2026.
- Total funding$100 million
- Expected awards20
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 1, 2023 |
|---|---|
| Deadline | January 16, 2024 |
| Archived by Grants.gov | February 15, 2024 |
Who can apply
This opportunity was open to any type of organization.
All 14 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Please note: Sections 317 and 318 of the PHS Act authorize funding to States, political subdivisions of States, and any other public and nonprofit private entities, but do not authorize awards to for-profit entities. Applicants who do not include Strategies A and B in the application will be deemed non-responsive and the application will not be reviewed. Applicants funded under Component C of PS20-2010 must clearly state that they are recipients or sub-recipients of Component C funding, and must clearly state whether they are proposing activities in a Component C-funded clinic. For verification of eligibility requirements, applicants are expected to upload a document confirming that the application includes Strategies A and B, stating whether they are recipients or sub-recipients of PS20-2010 Component C funding, and stating whether they are proposing activities in a Component C clinic. Applicants should name the file “Eligibility Verification” and upload it as a PDF file to the application submitted at www.grants.gov.
Is this a realistic fit?
- Most of the program's money (97% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to support the Ending the HIV Epidemic in the U.S. (EHE) initiative by scaling up HIV prevention and care services in sexual health clinics. Recipients funded under this NOFO will: 1) strengthen clinic infrastructure and improve service delivery to address the syndemic of HIV and other STIs, and 2) foster strategic partnerships in support of EHE.
Who has won Sexually Transmitted Diseases (STD) Prevention and Control Grants grants before
From fiscal 2021 to 2025, Sexually Transmitted Diseases (STD) Prevention and Control Grants (93.977) awarded $1.2 billion across 189 grant awards, an average of $6.1 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Department of State Health Services | Texas | 2 | $94.0 million |
| California Department of Public Health | California | 3 | $85.2 million |
| Florida Department of Health | Florida | 4 | $73.7 million |
| City of New York | New York | 5 | $48.7 million |
| County of Los Angeles | California | 2 | $37.1 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-PS-27-0008, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-PS-24-0003 still open?
No. It closed on January 16, 2024. A newer notice is forecast: CDC-RFA-PS-27-0008, expected deadline January 11, 2027.
Who can apply for Support and Scale Up of HIV Prevention Services in Sexual Health Clinics?
Centers for Disease Control - NCHHSTP accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Support and Scale Up of HIV Prevention Services in Sexual Health Clinics?
Closed January 16, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $100 million in total across about 20 awards.
Who has won Sexually Transmitted Diseases (STD) Prevention and Control Grants grants before?
The largest recipients over five fiscal years were Department of State Health Services, California Department of Public Health, Florida Department of Health. The program made 189 awards worth $1.2 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)